BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Freudenberg F, Broderick AL, Yu BB, Leonard MR, Glickman JN, Carey MC. Pathophysiological basis of liver disease in cystic fibrosis employing a DeltaF508 mouse model. Am J Physiol Gastrointest Liver Physiol 2008;294:G1411-20. [PMID: 18436622 DOI: 10.1152/ajpgi.00181.2007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Bodewes FA, van der Wulp MY, Beharry S, Doktorova M, Havinga R, Boverhof R, James Phillips M, Durie PR, Verkade HJ. Altered intestinal bile salt biotransformation in a cystic fibrosis ( Cftr−/− ) mouse model with hepato-biliary pathology. Journal of Cystic Fibrosis 2015;14:440-6. [DOI: 10.1016/j.jcf.2014.12.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
2 Drzymała-Czyż S, Dziedzic K, Szwengiel A, Krzyżanowska-Jankowska P, Nowak JK, Nowicka A, Aringazina R, Drzymała S, Kashirskaya N, Walkowiak J. Serum bile acids in cystic fibrosis patients-glycodeoxycholic acid as a potential marker of liver disease. Dig Liver Dis 2021:S1590-8658(21)00370-4. [PMID: 34305015 DOI: 10.1016/j.dld.2021.06.034] [Reference Citation Analysis]
3 Herrmann U, Dockter G, Lammert F. Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol. 2010;24:585-592. [PMID: 20955961 DOI: 10.1016/j.bpg.2010.08.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
4 Martin CR, Zaman MM, Ketwaroo GA, Bhutta AQ, Coronel E, Popov Y, Schuppan D, Freedman SD. CFTR dysfunction predisposes to fibrotic liver disease in a murine model. Am J Physiol Gastrointest Liver Physiol 2012;303:G474-81. [PMID: 22679000 DOI: 10.1152/ajpgi.00055.2012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
5 Tomati V, Sondo E, Armirotti A, Caci E, Pesce E, Marini M, Gianotti A, Jeon YJ, Cilli M, Pistorio A, Mastracci L, Ravazzolo R, Scholte B, Ronai Z, Galietta LJ, Pedemonte N. Genetic Inhibition Of The Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated To F508del Cystic Fibrosis Mutation. Sci Rep 2015;5:12138. [PMID: 26183966 DOI: 10.1038/srep12138] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
6 Falany CN, He D, Li L, Falany JL, Wilborn TW, Kocarek TA, Runge-Morris M. Regulation of hepatic sulfotransferase (SULT) 1E1 expression and effects on estrogenic activity in cystic fibrosis (CF). J Steroid Biochem Mol Biol 2009;114:113-9. [PMID: 19429440 DOI: 10.1016/j.jsbmb.2009.02.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
7 Salas-Silva S, Simoni-Nieves A, Razori MV, López-Ramirez J, Barrera-Chimal J, Lazzarini R, Bello O, Souza V, Miranda-Labra RU, Gutiérrez-Ruiz MC, Gomez-Quiroz LE, Roma MG, Bucio-Ortiz L. HGF induces protective effects in α-naphthylisothiocyanate-induced intrahepatic cholestasis by counteracting oxidative stress. Biochem Pharmacol 2020;174:113812. [PMID: 31954718 DOI: 10.1016/j.bcp.2020.113812] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
8 Ledder O, Haller W, Couper RT, Lewindon P, Oliver M. Cystic fibrosis: an update for clinicians. Part 2: hepatobiliary and pancreatic manifestations. J Gastroenterol Hepatol 2014;29:1954-62. [PMID: 25238538 DOI: 10.1111/jgh.12785] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
9 Bertolini A, van de Peppel IP, Doktorova-Demmin M, Bodewes FAJA, de Jonge H, Bijvelds M, Verkade HJ, Jonker JW. Defective FXR-FGF15 signaling and bile acid homeostasis in cystic fibrosis mice can be restored by the laxative polyethylene glycol. Am J Physiol Gastrointest Liver Physiol 2019;316:G404-11. [PMID: 30653340 DOI: 10.1152/ajpgi.00188.2018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
10 De Lisle RC, Borowitz D. The cystic fibrosis intestine. Cold Spring Harb Perspect Med. 2013;3:a009753. [PMID: 23788646 DOI: 10.1101/cshperspect.a009753] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 10.6] [Reference Citation Analysis]
11 Egan ME. How useful are cystic fibrosis mouse models? Drug Discovery Today: Disease Models 2009;6:35-41. [DOI: 10.1016/j.ddmod.2009.03.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
12 Rowland M, Bourke B. Liver disease in cystic fibrosis. Curr Opin Pulm Med 2011;17:461-6. [PMID: 21881510 DOI: 10.1097/MCP.0b013e32834b7f51] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
13 Debray D, Rainteau D, Barbu V, Rouahi M, El Mourabit H, Lerondel S, Rey C, Humbert L, Wendum D, Cottart CH. Defects in gallbladder emptying and bile Acid homeostasis in mice with cystic fibrosis transmembrane conductance regulator deficiencies. Gastroenterology. 2012;142:1581-1591.e6. [PMID: 22370478 DOI: 10.1053/j.gastro.2012.02.033] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
14 Olivier AK, Gibson-Corley KN, Meyerholz DK. Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology. Am J Physiol Gastrointest Liver Physiol 2015;308:G459-71. [PMID: 25591863 DOI: 10.1152/ajpgi.00146.2014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
15 Fisher JT, Zhang Y, Engelhardt JF. Comparative biology of cystic fibrosis animal models. Methods Mol Biol. 2011;742:311-334. [PMID: 21547741 DOI: 10.1007/978-1-61779-120-8_19] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
16 Atlas AB, Rosh JR. Cystic Fibrosis and Congenital Anomalies of the Exocrine Pancreas. Pediatric Gastrointestinal and Liver Disease. Elsevier; 2011. pp. 890-904.e5. [DOI: 10.1016/b978-1-4377-0774-8.10081-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Freudenberg F, Leonard MR, Liu SA, Glickman JN, Carey MC. Pathophysiological preconditions promoting mixed "black" pigment plus cholesterol gallstones in a DeltaF508 mouse model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol 2010;299:G205-14. [PMID: 20430874 DOI: 10.1152/ajpgi.00341.2009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
18 Stokes CS, Lammert F. Transporters in cholelithiasis. Biological Chemistry 2012;393:3-10. [DOI: 10.1515/bc-2011-226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
19 Acalovschi M. Gallstones in patients with liver cirrhosis: Incidence, etiology, clinical and therapeutical aspects. World J Gastroenterol 2014; 20(23): 7277-7285 [PMID: 24966598 DOI: 10.3748/wjg.v20.i23.7277] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
20 Messick J. A 21st-century approach to cystic fibrosis: optimizing outcomes across the disease spectrum. J Pediatr Gastroenterol Nutr 2010;51 Suppl 7:S1-7; quiz 3 p following S7. [PMID: 20739870 DOI: 10.1097/MPG.0b013e3181ec0242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Ikpa PT, Doktorova M, Meijsen KF, Nieuwenhuijze NDA, Verkade HJ, Jonker JW, de Jonge HR, Bijvelds MJC. Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice. Cell Mol Gastroenterol Hepatol 2020;9:47-60. [PMID: 31470114 DOI: 10.1016/j.jcmgh.2019.08.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
22 Miragoli F, Federici S, Ferrari S, Minuti A, Rebecchi A, Bruzzese E, Buccigrossi V, Guarino A, Callegari ML. Impact of cystic fibrosis disease on archaea and bacteria composition of gut microbiota. FEMS Microbiol Ecol 2017;93:fiw230. [PMID: 27810876 DOI: 10.1093/femsec/fiw230] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
23 Sondo E, Falchi F, Caci E, Ferrera L, Giacomini E, Pesce E, Tomati V, Mandrup Bertozzi S, Goldoni L, Armirotti A, Ravazzolo R, Cavalli A, Pedemonte N. Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia. Cell Chem Biol 2018;25:891-905.e8. [PMID: 29754957 DOI: 10.1016/j.chembiol.2018.04.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
24 Salas-Silva S, Simoni-Nieves A, Chávez-Rodríguez L, Gutiérrez-Ruiz MC, Bucio L, Quiroz LEG. Mechanism of cholangiocellular damage and repair during cholestasis. Ann Hepatol 2021;26:100530. [PMID: 34509686 DOI: 10.1016/j.aohep.2021.100530] [Reference Citation Analysis]
25 Bernhard W, Lange R, Graepler-Mainka U, Engel C, Machann J, Hund V, Shunova A, Hector A, Riethmüller J. Choline Supplementation in Cystic Fibrosis-The Metabolic and Clinical Impact. Nutrients 2019;11:E656. [PMID: 30889905 DOI: 10.3390/nu11030656] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Woods SE, Leonard MR, Hayden JA, Brophy MB, Bernert KR, Lavoie B, Muthupalani S, Whary MT, Mawe GM, Nolan EM, Carey MC, Fox JG. Impaired cholecystokinin-induced gallbladder emptying incriminated in spontaneous "black" pigment gallstone formation in germfree Swiss Webster mice. Am J Physiol Gastrointest Liver Physiol 2015;308:G335-49. [PMID: 25477375 DOI: 10.1152/ajpgi.00314.2014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
27 Vítek L, Carey MC. New pathophysiological concepts underlying pathogenesis of pigment gallstones. Clin Res Hepatol Gastroenterol 2012;36:122-9. [PMID: 21978438 DOI: 10.1016/j.clinre.2011.08.010] [Cited by in Crossref: 62] [Cited by in F6Publishing: 41] [Article Influence: 5.6] [Reference Citation Analysis]
28 D'Antonio M, Reyna J, Jakubosky D, Donovan MK, Bonder MJ, Matsui H, Stegle O, Nariai N, D'Antonio-Chronowska A, Frazer KA. Systematic genetic analysis of the MHC region reveals mechanistic underpinnings of HLA type associations with disease. Elife 2019;8:e48476. [PMID: 31746734 DOI: 10.7554/eLife.48476] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
29 Moyer K, Balistreri W. Hepatobiliary disease in patients with cystic fibrosis. Curr Opin Gastroenterol 2009;25:272-8. [PMID: 19381084 DOI: 10.1097/MOG.0b013e3283298865] [Cited by in Crossref: 67] [Cited by in F6Publishing: 15] [Article Influence: 5.2] [Reference Citation Analysis]
30 Li L, Somerset S. Digestive system dysfunction in cystic fibrosis: challenges for nutrition therapy. Dig Liver Dis 2014;46:865-74. [PMID: 25053610 DOI: 10.1016/j.dld.2014.06.011] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
31 Bodewes FAJA, Wouthuyzen-bakker M, Bijvelds MJ, Havinga R, de Jonge HR, Verkade HJ. Ursodeoxycholate modulates bile flow and bile salt pool independently from the cystic fibrosis transmembrane regulator ( Cftr ) in mice. American Journal of Physiology-Gastrointestinal and Liver Physiology 2012;302:G1035-42. [DOI: 10.1152/ajpgi.00258.2011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
32 Venneman NG, van Erpecum KJ. Pathogenesis of gallstones. Gastroenterol Clin North Am. 2010;39:171-83, vii. [PMID: 20478481 DOI: 10.1016/j.gtc.2010.02.010] [Cited by in Crossref: 88] [Cited by in F6Publishing: 60] [Article Influence: 7.3] [Reference Citation Analysis]
33 Van Erpecum KJ. Pathogenesis of cholesterol and pigment gallstones: an update. Clin Res Hepatol Gastroenterol. 2011;35:281-287. [PMID: 21353662 DOI: 10.1016/j.clinre.2011.01.009] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]